Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
FDA Advisory Committee Votes Unanimously to Confirm Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Early Alzheimer's Disease
BioArctic AB‘s partner Eisai announced that the US Food and Drug Administration’s (FDA) Peripheral and […]
Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer's Dementia Validation Trial
Cumulus Neuroscience, a global digital health company focused on advancing neuroscience clinical trials and patient […]
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
Eisai and Biogen announced today that Eisai has submitted a Marketing Authorization Application (MAA) for […]
Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
Therini Bio, a biotech company aimed at developing fibrin-targeted therapies to treat inflammatory neurodegenerative and […]
Otsuka and Lundbeck Issue Statement on FDA Advisory Committee Meeting on REXULTI® for the Treatment of Agitation Associated with Alzheimer’s Dementia
Otsuka Pharmaceutical and Lundbeck Pharmaceuticals announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee […]
BioArctic: Lecanemab Receives Priority Review Status in Japan
BioArctic AB’s partner Eisai has announced that the application for manufacturing and marketing approval for […]
Eisai Submits Marketing Autherization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
Eisai and Biogen have announced that Eisai has submitted a marketing authorization application (MAA) for […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more